The phase III CheckMate 498 trial evaluated nivolumab plus radiotherapy versus standard concurrent radiotherapy with temozolomide in newly diagnosed MGMT promoter–unmethylated GBM. The gene discussed is MGMT; the disease is glioblastoma.